Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines

Puay Hoon Tan; Gudi Mihir; Natthawadee Laokulrath; Emad Rakha

doi:10.1111/his.15117

Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines

Puay Hoon Tan, Gudi Mihir, Natthawadee Laokulrath, Emad Rakha

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

There have been recent updates on Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer (BC) published by the American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP), the European Society for Medical Oncology (ESMO) Expert Consensus statement, and the United Kingdom Working Group in 2023. These updates in guidelines specifically address issues and concerns on how to recognize the lower ends of the spectrum of HER2 staining. As per the 2018 ASCO-CAP HER2 guideline, the identification of “HER2-low” BCs is currently defined by those tumours that exhibit an immunohistochemistry (IHC) score of 1+ or score 2+ without gene amplification. Previously, BC patients with the HER2 low phenotype were not eligible for therapies that target HER2 oncogenic pathways and the distinction between IHC score 1+ and score 0 was of limited clinical impact. Therefore, pathologists did not pay close attention to such subclassification.

Original language	English
Pages (from-to)	715-718
Number of pages	4
Journal	Histopathology
Volume	84
Issue number	4
DOIs	https://doi.org/10.1111/his.15117
Publication status	Published - 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/his.15117

Cite this

@article{3bf71aca77784117ae2b0cefc7a1caaa,

title = "Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines",

abstract = "There have been recent updates on Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer (BC) published by the American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP), the European Society for Medical Oncology (ESMO) Expert Consensus statement, and the United Kingdom Working Group in 2023. These updates in guidelines specifically address issues and concerns on how to recognize the lower ends of the spectrum of HER2 staining. As per the 2018 ASCO-CAP HER2 guideline, the identification of “HER2-low” BCs is currently defined by those tumours that exhibit an immunohistochemistry (IHC) score of 1+ or score 2+ without gene amplification. Previously, BC patients with the HER2 low phenotype were not eligible for therapies that target HER2 oncogenic pathways and the distinction between IHC score 1+ and score 0 was of limited clinical impact. Therefore, pathologists did not pay close attention to such subclassification.",

author = "Tan, {Puay Hoon} and Gudi Mihir and Natthawadee Laokulrath and Emad Rakha",

year = "2024",

doi = "10.1111/his.15117",

language = "English",

volume = "84",

pages = "715--718",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines

AU - Tan, Puay Hoon

AU - Mihir, Gudi

AU - Laokulrath, Natthawadee

AU - Rakha, Emad

PY - 2024

Y1 - 2024

N2 - There have been recent updates on Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer (BC) published by the American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP), the European Society for Medical Oncology (ESMO) Expert Consensus statement, and the United Kingdom Working Group in 2023. These updates in guidelines specifically address issues and concerns on how to recognize the lower ends of the spectrum of HER2 staining. As per the 2018 ASCO-CAP HER2 guideline, the identification of “HER2-low” BCs is currently defined by those tumours that exhibit an immunohistochemistry (IHC) score of 1+ or score 2+ without gene amplification. Previously, BC patients with the HER2 low phenotype were not eligible for therapies that target HER2 oncogenic pathways and the distinction between IHC score 1+ and score 0 was of limited clinical impact. Therefore, pathologists did not pay close attention to such subclassification.

AB - There have been recent updates on Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer (BC) published by the American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP), the European Society for Medical Oncology (ESMO) Expert Consensus statement, and the United Kingdom Working Group in 2023. These updates in guidelines specifically address issues and concerns on how to recognize the lower ends of the spectrum of HER2 staining. As per the 2018 ASCO-CAP HER2 guideline, the identification of “HER2-low” BCs is currently defined by those tumours that exhibit an immunohistochemistry (IHC) score of 1+ or score 2+ without gene amplification. Previously, BC patients with the HER2 low phenotype were not eligible for therapies that target HER2 oncogenic pathways and the distinction between IHC score 1+ and score 0 was of limited clinical impact. Therefore, pathologists did not pay close attention to such subclassification.

UR - http://www.scopus.com/inward/record.url?scp=85179320204&partnerID=8YFLogxK

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1111/his.15117

U2 - 10.1111/his.15117

DO - 10.1111/his.15117

M3 - Article

C2 - 38087653

AN - SCOPUS:85179320204

SN - 0309-0167

VL - 84

SP - 715

EP - 718

JO - Histopathology

JF - Histopathology

IS - 4

ER -

Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this